Balance Sheet Account Details (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
|---|
| Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
| Schedule of Accounts Receivable |
| | | | | | | | | | | | | | | | | | | | September 30,
2023 | | | December 31,
2022 | | December 31,
2021 | | Accounts receivable, net: | | | | | | | | Accounts receivable, trade | $ | 9,023,000 | | | | $ | 7,315,000 | | | $ | 5,624,000 | | | Allowance for credit losses | (354,000) | | | | (293,000) | | | (690,000) | | | $ | 8,669,000 | | | | $ | 7,022,000 | | | $ | 4,934,000 | |
|
| Schedule of Allowance for Credit Losses |
Changes to the allowance for credit losses during the nine months ended September 30, 2023 were as follows: | | | | | | | Allowance for Credit Losses | | Balance as of January 1, 2023 | $ | (293,000) | | | Provision for expected credit loss | (98,000) | | Write-offs | 37,000 | | Balance as of September 30, 2023 | $ | (354,000) | |
|
| Schedule of Components of Inventories |
The components of inventories are as follows: | | | | | | | | | | | | | | September 30,
2023 | | December 31,
2022 | | Inventory: | | | | | Raw materials | $ | 7,590,000 | | | $ | 5,319,000 | | Work in process | 10,541,000 | | | 7,055,000 | | | Finished goods | 15,383,000 | | | 17,387,000 | | | $ | 33,514,000 | | | $ | 29,761,000 | | Inventories current | $ | 26,429,000 | | | $ | 29,761,000 | | Inventories non-current (included in other long-term assets) | $ | 7,085,000 | | | $ | — | |
|
| Schedule of Finite-Lived Intangible Assets |
Intangible assets that are subject to amortization consisted of the following for the periods presented: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | September 30, 2023 | | December 31, 2022 | | | Gross Carrying Amount | | Accumulated Amortization | | Net Carrying Amount | | Gross Carrying Amount | | Accumulated Amortization | | Net Carrying Amount | | Trade name | | $ | 2,630,000 | | | $ | (947,000) | | | $ | 1,683,000 | | | $ | 2,630,000 | | | $ | (552,000) | | | $ | 2,078,000 | | | Customer relationships | | 4,150,000 | | | (1,794,000) | | | 2,356,000 | | | 4,150,000 | | | (1,172,000) | | | 2,978,000 | | | Developed technology | | 41,600,000 | | | (9,975,000) | | | 31,625,000 | | | 41,600,000 | | | (5,615,000) | | | 35,985,000 | | | Intangibles, net | | $ | 48,380,000 | | | $ | (12,716,000) | | | $ | 35,664,000 | | | $ | 48,380,000 | | | $ | (7,339,000) | | | $ | 41,041,000 | |
|
| Schedule of Accrued Liabilities |
Accrued expenses consist of the following: | | | | | | | | | | | | | September 30,
2023 | | December 31,
2022 | | Compensation expenses | $ | 8,509,000 | | | $ | 7,002,000 | | | Customer deposits | 17,000 | | | 17,000 | | | Taxes payable | 724,000 | | | 825,000 | | | Insurance | 834,000 | | | 613,000 | | | Professional fees and royalties | 308,000 | | | 210,000 | | | Warranty liabilities | 572,000 | | | 489,000 | | | Accrued clinical study fees | 71,000 | | | 250,000 | | | Other | 517,000 | | | 1,146,000 | | | Total | $ | 11,552,000 | | | $ | 10,552,000 | |
|